<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898647</url>
  </required_header>
  <id_info>
    <org_study_id>PI2020_843_0109</org_study_id>
    <nct_id>NCT04898647</nct_id>
  </id_info>
  <brief_title>Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia</brief_title>
  <acronym>SLPRaresHvisc</acronym>
  <official_title>Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Saint Vincent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier de Lens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Walsdenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic&#xD;
      infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. Clinical&#xD;
      manifestations of the hyperviscosity syndrome (HVS) are related to the large amount of IgM in&#xD;
      circulating blood or to some physicochemical characteristics such as the presence of a&#xD;
      cryoglobulin property. Although HVS is one of the most frequent criteria for initiating&#xD;
      therapy in WM, few studies focused on its description and no diagnostic criteria are&#xD;
      available.&#xD;
&#xD;
      The present study aims to identify a diagnostic system for HVS, taking into account objective&#xD;
      symptoms such as bleedings, fundoscopic findings and also subjective symptoms such as fatigue&#xD;
      and comorbidities that may influence the severity of symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between items collected in questionnaires and HVS detection</measure>
    <time_frame>3 years</time_frame>
    <description>Correlation between items collected in questionnaires and HVS detection. Questionnaires are An oncogeriatric form for geriatric assessment, a comorbidity assessment form, a fatigue and quality of live assessment form, and an hemorrhagic assessment form.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between fundoscopic findings and HVS detection</measure>
    <time_frame>3 years</time_frame>
    <description>Correlation between fundoscopic findings and HVS detection</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hyperviscosity Syndrome</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Patients with confirmed HVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>presence of unexplained elsewhere fundoscopic abnormalities AND either IgM concentration above 30 g/L (densitometry) or cryoglobulin activity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with confirmed absence of HVS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Remaining patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fundoscopic picture</intervention_name>
    <description>A central review of numerised fundoscopic picture will be performed.</description>
    <arm_group_label>Patients with confirmed HVS</arm_group_label>
    <arm_group_label>Patients with confirmed absence of HVS</arm_group_label>
    <arm_group_label>Remaining patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>Two 10 ml blood vials will be sampled in addition to standard blood sampling for getting 6 to 7 200 μL aliquot.&#xD;
One 5 ml EDTA vial for GP1bα expression study, only if this sample can be sent to hemostasis laboratory within the 4 hours after sampling</description>
    <arm_group_label>Patients with confirmed HVS</arm_group_label>
    <arm_group_label>Patients with confirmed absence of HVS</arm_group_label>
    <arm_group_label>Remaining patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow sample</intervention_name>
    <description>Five to 10 ml bone marrow sample will be collected in addition to standard bone marrow sampling for getting molecular characteristics of WM</description>
    <arm_group_label>Patients with confirmed HVS</arm_group_label>
    <arm_group_label>Patients with confirmed absence of HVS</arm_group_label>
    <arm_group_label>Remaining patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with WM&#xD;
&#xD;
          -  Patients that may require a first-line or subsequent-line therapy&#xD;
&#xD;
          -  patients who will require treatment initiation&#xD;
&#xD;
          -  patients with serum monoclonal component concentration greater than 15 g/L and who&#xD;
             will underwent hyperviscosity assessment, even if hyperviscosity is not found and in&#xD;
             the absence of other treatment criteria, no treatment is finally initiated.&#xD;
&#xD;
          -  Patients agreeing to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with another chronic B-cell malignancy&#xD;
&#xD;
          -  patients with lymphoplasmacytic proliferations&#xD;
&#xD;
          -  patients with marginal zone lymphoma.&#xD;
&#xD;
          -  patients with WM and histologic transformation&#xD;
&#xD;
          -  Absence of informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Magalie JORIS, MD</last_name>
    <phone>03 22 45 54 19</phone>
    <email>joris.magalie@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magalie JORIS, MD</last_name>
      <phone>03.22.45.54.19</phone>
      <email>joris.magalie@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice JARDIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier TROUSSARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gandhi DAMAJ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie POULAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela ROBU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperviscosity Syndrome</keyword>
  <keyword>Waldenstrom Macroglobulinemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

